NIAID Testing Remdesivir Plus MS Drug for COVID-19 NIAID Testing Remdesivir Plus MS Drug for COVID-19
The ACTT-3 randomized controlled trial is testing the safety and efficacy remdesivir in combination with the immunomodulator interferon beta-1a in hospitalized COVID-19 patients.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - August 12, 2020 Category: Emergency Medicine Tags: Neurology & Neurosurgery News Source Type: news

NIH clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment begins
The study is anticipated to enroll more than 1,000 hospitalized adults with COVID-19. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 6, 2020 Category: American Health Source Type: news

Before a vaccine, we'll need treatments. Is interferon beta-1a a game changer? | Charlotte Summers
It ’s too early to say if the promising therapy can deliver. But it’s a vindication of the UK’s brilliant clinical trial infrastructureCharlotte Summers is a lecturer in intensive care medicine at the University of CambridgeCoronavirus – latest updatesAccording to the current UK government data, there have been nearly 300,000 confirmed cases of Covid-19, and more than45,000 people have died.The scale of this tragedy is therefore huge. And while a vaccine like the onebeing trialled by Oxford University will (hopefully) prevent or lessen the impact of the virus, it will not take away the need for ther...
Source: Guardian Unlimited Science - July 21, 2020 Category: Science Authors: Charlotte Summers Tags: Coronavirus outbreak Medical research Science Infectious diseases UK news Source Type: news

New 6-year data for Roche ’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis
             Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new analyses of Phase III OPERA I and OPERA II studies, as well as the open-label extensions, showing that OCREVUS ® (ocrelizumab) treatment reduced the risk of disease and disability progression in RMS and PPMS. These new analyses add additional evidence to the benefit-risk profile of OCREVUS, including the impact of MS on people’s daily lives. The data were selected for the 72nd American Academy of Neurolog y (AAN) Annual Meeting and will be made available onlin...
Source: Roche Investor Update - April 28, 2020 Category: Pharmaceuticals Source Type: news

New 6-year data for Roche ’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis
             Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new analyses of Phase III OPERA I and OPERA II studies, as well as the open-label extensions, showing that OCREVUS ® (ocrelizumab) treatment reduced the risk of disease and disability progression in RMS and PPMS. These new analyses add additional evidence to the benefit-risk profile of OCREVUS, including the impact of MS on people’s daily lives. The data were selected for the 72nd American Academy of Neurolog y (AAN) Annual Meeting and will be made available onlin...
Source: Roche Media News - April 28, 2020 Category: Pharmaceuticals Source Type: news

UPMC Health Plan reaches deal with pharmaceutical company for MS medications
UPMC Health Plan has reached a deal with a pharmaceutical company that will link reimbursement for two medications for multiple sclerosis to patient outcomes. Financial terms of the deal between UPMC Health Plan and Biogen (Nasdaq: BIIB) for Tecfidera and Avonex weren't announced. But this value-based agreement, the first of its kind, provides for reimbursement based on how well the drug keeps patients from further disability. Previous contracts have be en tied to health records and claims data. Yet… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 15, 2019 Category: Biotechnology Authors: Paul J. Gough Source Type: news

Company led drug alert: Avonex 30 micrograms/0.5ml solution for injection
Biogen Idec UK is recalling batches of Avonex 30 micrograms/0.5ml solution for injection as a precautionary measure due to a manufacturing issue. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 24, 2019 Category: Drugs & Pharmacology Source Type: news

PARADIGMS: Fingolimod Effective, Well Tolerated in Children PARADIGMS: Fingolimod Effective, Well Tolerated in Children
Results show an 82% reduced annualized relapse rate among pediatric patients with multiple sclerosis taking fingolimod compared with those taking interferon-beta1a.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

New Drug Could Help Kids With MS
The first drug approved for use in children with MS reduced relapse rates by 82 percent in people aged 10 to 17 compared with interferon beta-1a, a drug commonly used to slow the progression of the degenerative nerve disease. (Source: WebMD Health)
Source: WebMD Health - September 13, 2018 Category: Consumer Health News Source Type: news

Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
WEDNESDAY, Sept. 12, 2018 -- Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events than interferon beta-1a, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 12, 2018 Category: Pharmaceuticals Source Type: news

Improved Disability, Cognition With Ocrelizumab in MS Improved Disability, Cognition With Ocrelizumab in MS
Extension data from phase 3 clinical trials show greater improvements in patients who continued receiving ocrelizumab than in those who switched from interferon beta-1a.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions(1) In a pivotal Phase III study, oral fingolimod significantly reduced relapses by 82% in a pediatric patient population vs. interferon beta-1a ... Biopharmaceuticals, Neurology, FDA Novartis, Gilenya, Fingolimod, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2017 Category: Pharmaceuticals Source Type: news

John Walsh, M.D. Joins EMD Serono as Vice President of Neurology and Immunology, US Medical Affairs
ROCKLAND, Mass., Dec. 7, 2017 -- (Healthcare Sales & Marketing Network) -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced the appointment of John Walsh, M.D. as Vice President, Neurology ... Biopharmaceuticals, Personnel EMD Serono, Merck KGaA, Rebif, interferon (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 7, 2017 Category: Pharmaceuticals Source Type: news

Ocrelizumab Linked to Improved Visual Outcomes in Relapsing MS Ocrelizumab Linked to Improved Visual Outcomes in Relapsing MS
In pooled analysis from the phase 3 OPERA trials, low-contrast letter acuity showed improved visual outcomes in MS after treatment with ocrelizumab over interferon beta-1a.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 27, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

The Non-Pharma Pharma Company?
Across all industries, consumers are demanding more and companies are responding, adapting their commercial models in efforts to meet their customers ’ evolving needs.Pharma is not immune to these wider changes and most companies are actively rethinking the traditional model to ensure they can compete in an increasingly multi-channel, multi-stakeholder environment.Healthcare is going through an “amazing transformation process” driven by new media, says Tim Kneen, Executive President at Merck. “The standard pharma business model of high volume, get access, make as much noise as possible will not be r...
Source: EyeForPharma - June 29, 2017 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news

The Non-Pharma Pharma Company?
Across all industries, consumers are demanding more and companies are responding, adapting their commercial models in efforts to meet their customers ’ evolving needs.Pharma is not immune to these wider changes and most companies are actively rethinking the traditional model to ensure they can compete in an increasingly multi-channel, multi-stakeholder environment.Healthcare is going through an “amazing transformation process” driven by new media, says Tim Kneen, Executive President at Merck. “The standard pharma business model of high volume, get access, make as much noise as possible will not be r...
Source: EyeForPharma - June 29, 2017 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news

Celgene's multiple sclerosis drug succeeds in late-stage trial
(Reuters) - Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - May 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy. In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen said it was cooperating with the federal probe, it did not provide any other specific details. Get the full story at our sister site, Drug Delivery Business News. T...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Legal News Neurological Pharmaceuticals Wall Street Beat Biogen Source Type: news

Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera. Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera. Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 2, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Rebif (Interferon beta-1a) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 25, 2017 Category: Drugs & Pharmacology Source Type: news

New drug proves effective for both types of MS
Conclusion This study shows promising results for a new approach to treating MS. However, the study period is relatively short (96 weeks is about 20 months, so less than two years) and MS is a long-term disease. If this drug is approved for use, longer studies will be needed to be sure that this treatment lives up to its early promise over many years and to monitor for adverse reactions in real life, particularly cancers. Some people with relapsing remitting MS do well on existing treatments, and have only infrequent relapses of mild symptoms which get worse very slowly. But for most patients on standard treatment, the dam...
Source: NHS News Feed - December 22, 2016 Category: Consumer Health News Tags: Neurology Medication Source Type: news

Roche says new MS drug works better than Merck's Rebif
ZURICH (Reuters) - Roche said on Wednesday its Ocrevus multiple sclerosis drug controlled the most common form of the disease better than a rival's medicine and worked against another form of MS for which there is no approved treatment. (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Avonex (interferon beta 1a injection)
Title: Avonex (interferon beta 1a injection) Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 6/8/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 8, 2016 Category: Drugs & Pharmacology Source Type: news

Ocrelizumab bests interferon for relapsing MS at 2 years
VANCOUVER – Ocrelizumab, a B-cell depleting humanized monoclonal antibody being developed by Hoffman–La Roche, consistently outperformed interferon beta-1a (Rebif) for relapsing multiple sclerosis in... (Source: Family Practice News)
Source: Family Practice News - May 25, 2016 Category: Primary Care Source Type: news

Ocrelizumab bests interferon for relapsing MS at 2 years
VANCOUVER – Ocrelizumab, a B-cell depleting humanized monoclonal antibody being developed by Hoffman–La Roche, consistently outperformed interferon beta-1a (Rebif) for relapsing multiple sclerosis in... (Source: Clinical Neurology News)
Source: Clinical Neurology News - May 25, 2016 Category: Neurology Source Type: news

Avonex (Interferon beta-1a) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 5, 2016 Category: Drugs & Pharmacology Source Type: news

Biogen reports positive data of daclizumab over interferon beta-1a im to treat multiple sclerosis
Global biotechnology company Biogen has reported new data that demonstrates daclizumab’s positive cognitive outcomes, targeted and reversible mechanism of action (MOA), and safety profile over interferon beta-1a im in relapsing-remitting multiple scl… (Source: Drug Development Technology)
Source: Drug Development Technology - May 4, 2016 Category: Pharmaceuticals Source Type: news

Merck KGaA bets on cancer drugs to revitalize German firm
TEL AVIV (Reuters) - Merck KGaA is betting on its oncology pipeline to revitalize the German drugmaker as it sees falling sales from its best-selling medicine, multiple sclerosis treatment Rebif. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Positive Topline Results for Investigational MS DrugPositive Topline Results for Investigational MS Drug
Two phase 3 studies suggest the investigational drug ocrelizumab is superior to interferon beta-1a in reducing the relapse rate in patients with relapsing multiple sclerosis. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 9, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Positive Topline Results for Investigational MS DrugPositive Topline Results for Investigational MS Drug
Two phase 3 studies suggest the investigational drug ocrelizumab was superior to interferon beta-1a in reducing the relapse rate in patients with relapsing multiple sclerosis. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Roche’s ocrelizumab significantly reduced both relapses and disability progression versus interferon beta-1a (Rebif®) in two Phase III studies in multiple sclerosis
Roche today announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif®), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease. (Source: Roche Investor Update)
Source: Roche Investor Update - June 30, 2015 Category: Pharmaceuticals Source Type: news

Roche’s ocrelizumab significantly reduced both relapses and disability progression versus interferon beta-1a (Rebif®) in two Phase III studies in multiple sclerosis
Roche today announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif®), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease. (Source: Roche Media News)
Source: Roche Media News - June 30, 2015 Category: Pharmaceuticals Source Type: news

Ocrelizumab trial results
Two phase III studies of a potential new injected disease modifying drug for relapsing remitting MS show that it "significantly reduced" relapses, new lesions and the build up of disability compared to Rebif. The manufacturer plans to submit the drug for licensing next year. A phase III trial in primary progressive MS is due to report later this year. Reuters Roche press release Ocrelizumab - drugs in development (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 30, 2015 Category: Neurology Source Type: news

Plegridy compared to other disease modifying drugs
A meta analysis comparison of pegylated interferon beta 1a (Plegridy) and other injected disease modifying drugs found that its safety and efficacy were similar to the older drugs. MS News Today Disease modifying drugs for relapsing MS - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 8, 2015 Category: Neurology Source Type: news

Positive interim results from major UK study on MS drugs
Results of the analysis of the 6 year data of the Department of Health (DH) MS Risk-sharing Scheme (RSS), published in the Lancet Neurology today, show that the disease modifying drugs Avonex, Betaferon, Copaxone and Rebif are cost effective and are clinically effective in reducing the progression of the disease in people with relapsing remitting multiple sclerosis (MS). (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 2, 2015 Category: Neurology Source Type: news

EMD Serono launches app to help patients verify medicine
In a move likely to be replicated over the next couple years by other drug firms, Rockland-based EMD Serono has launched an app that allows patients to scan its prescription drugs with a smartphone in order to verify that they aren't counterfeit. The maker of drugs like Rebif for multiple sclerosis and fertility medicine Gonal-F announced today that its app, Check My Meds, is now available to download for iPhones and Android phones. Kimberly Fleming, associate director of product security and outbound… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - December 10, 2014 Category: Hospital Management Authors: Don Seiffert Source Type: news

FDA approves once-a-year multiple sclerosis drug by Genzyme with warnings
Genzyme's once-a-year drug to treat multiple sclerosis hasbeen approved with a boxed warning noting a risk of serious side effects. The approval comes more than 10 months after the drug was rejected by U.S. regulators. The rejection last December came about because the U.S. Food and Drug Administration prefers trials in which patients are blinded to which drug they are taking. Genzyme's trials tested more than 1,600 patients, comparing Lemtrada to EMD Serono's drug, Rebif. Since the two drugs have… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - November 15, 2014 Category: Hospital Management Authors: Don Seiffert Source Type: news

FDA approves once-a-year multiple sclerosis drug by Genzyme with warnings
Genzyme's once-a-year drug to treat multiple sclerosis hasbeen approved with a boxed warning noting a risk of serious side effects. The approval comes more than 10 months after the drug was rejected by U.S. regulators. The rejection last December came about because the U.S. Food and Drug Administration prefers trials in which patients are blinded to which drug they are taking. Genzyme's trials tested more than 1,600 patients, comparing Lemtrada to EMD Serono's drug, Rebif. Since the two drugs have… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 15, 2014 Category: Biotechnology Authors: Don Seiffert Source Type: news

Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry
BOSTON (MedPage Today) -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 12, 2014 Category: Journals (General) Source Type: news

Peg-Interferon for MS Wins FDA Nod
(MedPage Today) -- A pegylated form of interferon-beta-1a (Plegridy) that can be administered once every 2 weeks in patients with relapsing multiple sclerosis was approved by the FDA, its manufacturer said. (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - August 17, 2014 Category: Neurology Source Type: news

Biogen wins U.S. approval of long acting multiple sclerosis drug
NEW YORK (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment. (Source: Reuters: Health)
Source: Reuters: Health - August 16, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Peginterferon beta-1a (Plegridy) licensed
The European Commission has approved the licensing of peginterferon beta-1a (Plegridy) for treating relapsing remitting MS. The drug is a longer lasting version of interferon beta 1a that only needs to be injected once a fortnight. It has similar therapeutic effects and side effects to interferon beta 1a. Biogen Idec press release Peginterferon beta-1a (Plegridy) (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - July 24, 2014 Category: Neurology Source Type: news

European Union Approves Peginterferon in MS European Union Approves Peginterferon in MS
Approval is based on the ADVANCE study, showing the pegylated version of interferon beta-1a dosed every 2 weeks reduces relapses and disability progression and has a favorable safety profile. International Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 23, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

MS Drug Linked As Possible Cause Of Thrombotic Microangiopathy
In a letter in the March 27th issue of the New England Journal of Medicine, Scottish researchers announced that they’d found evidence linking the MS drug Rebif to the formation of “thrombotic microangiopathy.” This condition causes serious blood clots to form in small blood vessels in different parts of the body. The condition is rare, but it is potentially life threatening. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 4, 2014 Category: Pharmaceuticals Source Type: news

Biogen Buys Rights to Experimental Alzheimer’s Drugs
Biogen Idec Inc., maker of the multiple sclerosis drugs Avonex, Tysabri and Tecfidera, bought rights to Japan’s Eisai Co.’s experimental Alzheimer’s disease medicines as it seeks to add treatments for brain disorders. Biogen will pay Eisai an upfront payment, and a fixed amount of development and milestones as the drugs... (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 7, 2014 Category: Pharmaceuticals Source Type: news

Low-Contrast Visual Tests Reveal Better Alemtuzumab EfficacyLow-Contrast Visual Tests Reveal Better Alemtuzumab Efficacy
Standard visual acuity testing misses some visual dysfunction in patients with MS. Sloan low-contrast acuity testing revealed superior efficacy for alemtuzumab over interferon beta-1a in CARE-MS I. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Biweekly Dosing of Pegylated Interferon Reduces MS RelapsesBiweekly Dosing of Pegylated Interferon Reduces MS Relapses
Pegylated interferon beta-1a given every 2 or 4 weeks significantly reduced multiple sclerosis relapse rates. Biweekly dosing was superior to placebo for all clinical and radiologic outcomes. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 11, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Switching to Novartis drug Gilenya
Two new analyses from the Phase III TRANSFORMS study presented at the 23rd meeting of the European Neurological Society (ENS) in Barcelona, demonstrated how Novartis' Gilenya® (fingolimod) was effective against all four key measures of disease activity in multiple sclerosis (MS) - brain volume loss, lesion activity (measured by magnetic resonance imaging - MRI), relapse rates and disability progression. Improvements were seen in patients who switched from standard interferon (interferon beta-1a) treatment to Gilenya within 12 months of the switch and up to the end of the 4.5 year extension study. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 11, 2013 Category: Drugs & Pharmacology Source Type: news